Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer

Breast Cancer Clinical Trial

Official title:

Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01023204
• Other study ID #: CA139-371
• Status: Completed
• Phase: Phase 2
• First received: November 30, 2009
• Last updated: February 2, 2010
• Start date: October 2002
• Est. completion date: July 2005

Study information

• Verified date: December 2009
• Source: Bristol-Myers Squibb
• Contact: n/a
• Is FDA regulated: No
• Health authority: Japan: Pharmaceuticals and Medical Devices Agency
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and the safety of paclitaxel given weekly in patients with advanced or recurrent breast cancer

Recruitment information / eligibility

• Status: Completed
• Enrollment: 68
• Est. completion date: July 2005
• Est. primary completion date: July 2005
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years to 74 Years

Eligibility

Inclusion Criteria:

• Patients with primary advanced inoperable disease who were refractory to chemotherapy

• Patients with recurrent disease following post-operative adjuvant chemotherapy

• Patients who were not amenable to post-recurrence chemotherapy

Exclusion Criteria:

• Patients with serious, uncontrolled medical illness

• Patients with previous therapy with taxanes

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Paclitaxel
Solution, IV, 100 mg/m², weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bristol-Myers Squibb

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response rate [defined as total number of patients with complete and partial response divided by number of response-evaluable patients] based on predetermined evaluation criteria		Each 49 day course of treatment until withdrawal or unacceptable toxicity	No
Primary	Safety: incidence and severity of adverse events, laboratory test abnormalities		Each 49 day course of treatment until withdrawal or unacceptable toxicity	Yes
Secondary	Duration of response, defined as either Complete or Partial Response, based on Evaluation Criteria on Therapeutic Effects in Patients with Advanced or Recurrent Breast Cancer		Each 49 day course of treatment until withdrawal or unacceptable toxicity	No

External Links

•   BMS Clinical Trials Disclosure
•   For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm
•   Investigator Inquiry form